NCT06522334

Brief Summary

The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death. There are no additional interventions regarding this registry.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
400

participants targeted

Target at P75+ for all trials

Timeline
95mo left

Started Feb 2024

Longer than P75 for all trials

Geographic Reach
1 country

5 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress22%
Feb 2024Feb 2034

Study Start

First participant enrolled

February 28, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

July 22, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 26, 2024

Completed
9.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2034

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2034

Last Updated

March 14, 2025

Status Verified

March 1, 2025

Enrollment Period

10 years

First QC Date

July 22, 2024

Last Update Submit

March 11, 2025

Conditions

Interstitial Lung Disease

Outcome Measures

Primary Outcomes (2)

  • Mortality

    Mortality caused by interstitial lung disease

    10 years

  • Loss of lung function

    FVC and DLCO loss within 24 months

    2 years

Secondary Outcomes (2)

  • Prevalence

    10 years

  • Response to drugs

    10 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Everybody with a diagnosis of interstitial lung disease, over 18 years old will be asked to participate.

You may qualify if:

  • diagnosis of interstitial lung disease
  • written informed consent

You may not qualify if:

  • to not comprehend and rightfully judge participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Klinik Hietzing

Vienna, 1130, Austria

RECRUITING

Klinik Penzing

Vienna, 1140, Austria

RECRUITING

Ludwig Boltzmann Institut for Lung Health

Vienna, 1140, Austria

RECRUITING

Klinik Ottakring

Vienna, 1160, Austria

RECRUITING

Klinik Floridsdorf

Vienna, 1210, Austria

RECRUITING

MeSH Terms

Conditions

Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Department for Internal Medicine and Pneumology Clinic Hietzing

Study Record Dates

First Submitted

July 22, 2024

First Posted

July 26, 2024

Study Start

February 28, 2024

Primary Completion (Estimated)

February 28, 2034

Study Completion (Estimated)

February 28, 2034

Last Updated

March 14, 2025

Record last verified: 2025-03

Locations

AU(5)